人福医药 (600079.SH)
19.97 -0.48(-2.350%)
+ 收藏
今开:20.37 最高:20.55 成交量:32.14万手
昨收:20.45 最低:19.90 成交额:6.44亿
利润表(人福医药)
上市前/上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 | 上市后 |
报表类型 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 | 合并报表 |
一、营业总收入(元) | 19,143,374,654.64 | 12,861,283,334.71 | 6,367,371,531.88 | 24,524,740,572.69 | 18,111,717,932.04 | 12,382,998,383.93 | 6,225,735,090.21 |
营业收入(元) | 19,143,374,654.64 | 12,861,283,334.71 | 6,367,371,531.88 | 24,524,740,572.69 | 18,111,717,932.04 | 12,382,998,383.93 | 6,225,735,090.21 |
二、营业总成本(元) | 16,644,223,107.45 | 11,126,432,608.62 | 5,584,162,042.55 | 21,417,059,137.08 | 15,716,222,804.26 | 10,673,265,170.64 | 5,431,915,788.85 |
营业成本(元) | 10,192,306,440.83 | 6,844,655,355.35 | 3,412,875,696.10 | 13,290,991,557.35 | 9,806,286,791.95 | 6,736,431,518.17 | 3,335,010,236.10 |
研发费用(元) | 1,093,259,846.85 | 705,834,992.85 | 349,340,705.03 | 1,461,942,028.60 | 1,001,169,520.67 | 641,222,312.00 | 285,358,236.04 |
营业税金及附加(元) | 160,955,318.04 | 104,285,980.11 | 51,186,293.93 | 191,747,055.27 | 124,599,985.06 | 97,193,328.65 | 49,550,717.62 |
销售费用(元) | 3,477,070,885.85 | 2,380,822,325.92 | 1,203,802,252.65 | 4,397,798,774.97 | 3,360,835,097.39 | 2,361,665,417.95 | 1,272,496,388.82 |
管理费用(元) | 1,393,358,750.94 | 935,874,304.57 | 486,502,809.84 | 1,770,060,888.32 | 1,211,650,068.82 | 724,130,879.81 | 367,722,651.90 |
财务费用(元) | 327,271,864.94 | 154,959,649.82 | 80,454,285.00 | 304,518,832.57 | 211,681,340.37 | 112,621,714.06 | 121,777,558.37 |
其中:利息费用(元) | 269,916,260.54 | 178,694,372.28 | 85,200,005.56 | 354,141,696.04 | 267,659,212.16 | 173,458,585.78 | 94,235,280.81 |
其中:利息收入(元) | 40,151,700.63 | 33,601,816.20 | 13,685,685.29 | 58,771,065.02 | 39,494,643.88 | 18,573,116.39 | 7,210,554.99 |
三、其他经营收益 | |||||||
加:公允价值变动收益(元) | -7,258,698.89 | -5,660,932.78 | -6,536,363.61 | 136,854,734.94 | 104,016,622.49 | 88,927,090.76 | 90,650,758.98 |
加:投资收益(元) | 80,482,162.86 | 28,708,651.29 | 16,870,550.16 | 206,785,478.83 | 196,144,860.74 | 188,012,813.80 | 106,784,674.41 |
其中:对联营企业和合营企业的投资收益(元) | 48,936,102.58 | 35,124,357.40 | 20,275,301.77 | 59,991,711.04 | 45,708,090.53 | 35,246,854.09 | 22,639,587.69 |
资产处置收益(元) | -3,113,228.19 | -532,848.97 | 513,191.27 | -1,084,924.95 | 655,096.12 | 37,940.24 | 391,415.86 |
资产减值损失(元) | -4,248,993.13 | -4,036,730.68 | 986,604.69 | -61,407,302.82 | -28,746,644.43 | -29,215,446.98 | 249,327.65 |
信用减值损失(元) | -48,798,603.11 | -30,068,997.03 | -16,877,771.55 | -147,357,909.38 | -54,213,689.24 | -47,870,921.41 | -24,472,100.75 |
其他收益(元) | 139,499,178.04 | 96,923,675.50 | 44,347,913.76 | 205,702,658.11 | 129,881,762.19 | 96,621,572.76 | 43,961,299.67 |
四、营业利润(元) | 2,655,713,364.77 | 1,820,183,543.42 | 822,513,614.05 | 3,447,174,170.34 | 2,743,233,135.65 | 2,006,246,262.46 | 1,011,384,677.18 |
加:营业外收入(元) | 6,481,674.13 | 1,265,964.16 | 627,700.46 | 8,284,582.89 | 1,410,000.85 | 1,948,752.76 | 2,250,674.52 |
减:营业外支出(元) | 73,211,831.95 | 45,981,154.96 | 13,616,262.67 | 71,629,921.26 | 37,366,699.47 | 15,746,079.72 | 10,428,505.59 |
五、利润总额(元) | 2,588,983,206.95 | 1,775,468,352.62 | 809,525,051.84 | 3,383,828,831.97 | 2,707,276,437.03 | 1,992,448,935.50 | 1,003,206,846.11 |
减:所得税费用(元) | 481,602,428.62 | 319,838,000.16 | 161,336,256.36 | 568,563,020.27 | 424,125,720.65 | 301,761,452.13 | 142,093,319.60 |
六、净利润(元) | 2,107,380,778.33 | 1,455,630,352.46 | 648,188,795.48 | 2,815,265,811.70 | 2,283,150,716.38 | 1,690,687,483.37 | 861,113,526.51 |
(一)按经营持续性分类 | |||||||
持续经营净利润(元) | 2,107,380,778.33 | 1,455,630,352.46 | 648,188,795.48 | 2,815,265,811.70 | 2,283,150,716.38 | 1,690,687,483.37 | 861,113,526.51 |
(二)按所有权归属分类 | |||||||
归属于母公司股东的净利润(元) | 1,589,694,392.14 | 1,111,094,974.15 | 486,392,045.37 | 2,134,484,688.96 | 1,768,711,274.43 | 1,323,812,531.77 | 665,316,964.81 |
少数股东损益(元) | 517,686,386.19 | 344,535,378.31 | 161,796,750.11 | 680,781,122.74 | 514,439,441.95 | 366,874,951.60 | 195,796,561.70 |
扣除非经常性损益后的净利润(元) | 1,521,128,177.12 | 1,089,008,272.54 | 464,342,153.96 | 1,822,141,598.15 | 1,503,003,418.79 | 1,071,058,920.91 | 508,455,478.82 |
七、每股收益 | |||||||
一、基本每股收益(元) | 0.98 | 0.68 | 0.30 | 1.32 | 1.09 | 0.82 | 0.41 |
二、稀释每股收益(元) | 0.97 | 0.68 | 0.30 | 1.31 | 1.09 | 0.81 | 0.41 |
八、其他综合收益(元) | 121,805,252.07 | -133,563,877.30 | -35,025,830.50 | 32,370,529.47 | 88,219,201.66 | 62,058,474.86 | 1,583,453.59 |
归属于母公司股东的其他综合收益(元) | 131,483,333.54 | -124,962,560.43 | -31,008,824.54 | 36,319,681.82 | 87,940,098.17 | 58,409,343.13 | 1,349,275.18 |
归属于少数股东的其他综合收益(元) | -9,678,081.47 | -8,601,316.87 | -4,017,005.96 | -3,949,152.35 | 279,103.49 | 3,649,131.73 | 234,178.41 |
九、综合收益总额(元) | 2,229,186,030.40 | 1,322,066,475.16 | 613,162,964.98 | 2,847,636,341.17 | 2,371,369,918.04 | 1,752,745,958.23 | 862,696,980.10 |
归属于母公司所有者的综合收益总额(元) | 1,721,177,725.68 | 986,132,413.72 | 455,383,220.83 | 2,170,804,370.78 | 1,856,651,372.60 | 1,382,221,874.90 | 666,666,239.99 |
归属于少数股东的综合收益总额(元) | 508,008,304.72 | 335,934,061.44 | 157,779,744.15 | 676,831,970.39 | 514,718,545.44 | 370,524,083.33 | 196,030,740.11 |
公告日期 | 2024-10-30 | 2024-07-27 | 2024-04-30 | 2024-03-29 | 2023-10-27 | 2023-08-25 | 2023-04-28 |
审计意见(境内) | 标准无保留意见 | ||||||
原始财报文件下载 | 下载财报(PDF) | 下载财报(PDF) | 下载财报(PDF) | 下载财报(PDF) | 下载财报(PDF) | 下载财报(PDF) | 下载财报(PDF) |
上市前/上市后 |
报表类型 |
一、营业总收入(元) |
营业收入(元) |
二、营业总成本(元) |
营业成本(元) |
研发费用(元) |
营业税金及附加(元) |
销售费用(元) |
管理费用(元) |
财务费用(元) |
其中:利息费用(元) |
其中:利息收入(元) |
三、其他经营收益 |
加:公允价值变动收益(元) |
加:投资收益(元) |
其中:对联营企业和合营企业的投资收益(元) |
资产处置收益(元) |
资产减值损失(元) |
信用减值损失(元) |
其他收益(元) |
四、营业利润(元) |
加:营业外收入(元) |
减:营业外支出(元) |
五、利润总额(元) |
减:所得税费用(元) |
六、净利润(元) |
(一)按经营持续性分类 |
持续经营净利润(元) |
(二)按所有权归属分类 |
归属于母公司股东的净利润(元) |
少数股东损益(元) |
扣除非经常性损益后的净利润(元) |
七、每股收益 |
一、基本每股收益(元) |
二、稀释每股收益(元) |
八、其他综合收益(元) |
归属于母公司股东的其他综合收益(元) |
归属于少数股东的其他综合收益(元) |
九、综合收益总额(元) |
归属于母公司所有者的综合收益总额(元) |
归属于少数股东的综合收益总额(元) |
公告日期 |
审计意见(境内) |
原始财报文件下载 |
Showing 1 to 45 of 45 entries